From: Concurrent use of opioids and stimulants and risk of fatal overdose: A cohort study
Ā | Unadjusted Estimates | Adjusted Estimate | ||
---|---|---|---|---|
HR (95%CI) | P-value | HR (95%CI) | P-value | |
Substance use type | ||||
āBoth | 1Ā·94 (1Ā·45-2Ā·61) | <ā0Ā·001 | 2Ā·02 (1Ā·47-2Ā·78) | <ā0Ā·001 |
āStimulant | 0Ā·99 (0Ā·72-1Ā·35) | 0Ā·9322 | 1Ā·05(0Ā·75-1Ā·48) | 0Ā·7644 |
āOpioid | Reference | |||
Sex-Female | 0Ā·54 (0Ā·41-0Ā·70) | <ā0Ā·001 | 0Ā·53 (0Ā·40-0Ā·69) | <ā0Ā·001 |
Age | ||||
āā<ā30 | 0Ā·92 (0Ā·67-1Ā·28) | 0Ā·6249 | 1Ā·07 (0Ā·75-1Ā·52) | 0Ā·7112 |
ā30-39 | 0Ā·68(0Ā·48-0Ā·96) | 0Ā·0305 | 0Ā·74(0Ā·51-1Ā·06) | 0Ā·0974 |
ā40-49 | 1Ā·07(0Ā·77-1Ā·48) | 0Ā·6988 | 1Ā·08(0Ā·78-1Ā·51) | 0Ā·6335 |
ā50+ | Reference | |||
Health Authority | ||||
āFraser | 0Ā·68 (0Ā·50-0Ā·92) | 0Ā·0117 | 0Ā·79 (0Ā·58-1Ā·07) | 0Ā·1270 |
āInterior | 0Ā·85(0Ā·60-1Ā·20) | 0Ā·3479 | 1Ā·01(0Ā·71-1Ā·44) | 0Ā·9440 |
āNorthern | 0Ā·56(0Ā·32-0Ā·99) | 0Ā·0449 | 0Ā·70 (0Ā·40-1Ā·23) | 0Ā·2163 |
āVancouver Island | 0Ā·79(0Ā·55-1Ā·14) | 0Ā·2131 | 1Ā·01 (0Ā·69-1Ā·47) | 0Ā·9642 |
āVancouver Coastal | Reference | |||
Elixhauser index | ||||
āNone | 0Ā·82 (0Ā·61-1Ā·12) | 0Ā·2167 | 0Ā·96 (0Ā·69-1Ā·33) | 0Ā·8128 |
ā1 | 0Ā·78(0Ā·56-1Ā·10) | 0Ā·1536 | 0Ā·89(0Ā·63-1Ā·26) | 0Ā·5260 |
ā2 | 0Ā·67(0Ā·47-0Ā·95) | 0Ā·0248 | 0Ā·71(0Ā·49-1Ā·01) | 0Ā·0564 |
ā3+ | Reference | |||
Benzodiazepine | 1Ā·27 (0Ā·93-1Ā·73) | 0Ā·1317 | 1Ā·19 (0Ā·85-1Ā·67) | 0Ā·3135 |
Z-drugs | 1Ā·35(0Ā·90-2Ā·04) | 0Ā·1521 | 1Ā·21(0Ā·79-1Ā·86) | 0Ā·3863 |
Sedatives | 1Ā·23(0Ā·97-1Ā·58) | 0Ā·0927 | 1Ā·04(0Ā·77-1Ā·41) | 0Ā·7836 |
Opioids for pain | 1Ā·16(0Ā·87-1Ā·55) | 0Ā·3164 | 1Ā·15(0Ā·82-1Ā·60) | 0Ā·4152 |